Skip to content


Working toward a world without infectious disease

First Investment: 2015
EXIT - Acquisition (Vir Biotechnology: VIR)

HIV, hepatitus B, flu, tuber­cu­losis, COVID-19: these deadly infectious diseases persist because they overwhelm the human immune system, and because previous treatments have failed to target their vulner­a­bil­i­ties. Vir is coun­ter­at­tacking on multiple fronts. It engineers new antibodies to neutralize pathogens, uses viral vectors to reprogram T cells to be more potent, finds ways to boost the innate immune system, and uses small interfering RNA molecules to suppress viral replication. Vir Biotech­nology acquired Agenovir in 2018.

Explore Companies